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Background: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is a rare autosomal recessive renal
disease characterized by tubular disorders at the thick ascending limb of Henle’s loop. It is caused by mutations in
the tight junction structural proteins claudin-16 or claudin-19, which are encoded by the CLDN16 and CLDN19
genes, respectively. Patients exhibit excessive wasting of calcium and magnesium, nephrocalcinosis, chronic kidney
disease, and early progression to end-stage renal failure during infancy.
Case presentation: We here report the phenotype and molecular analysis of a female Brazilian patient with a novel
large homozygous deletion in the CLDN16 gene. The proband, born from consanguineous parents, presented the first
symptoms at age 20. Clinical examination revealed hypocalcemia, hypomagnesemia, nephrocalcinosis, mild myopia,
high serum levels of uric acid and intact parathyroid hormone, and moderate chronic kidney disease (stage 3). She and
her mother were subjected to CLDN16 and CLDN19 mutational analysis. In addition, the multiplex ligation-dependent
probe amplification method was used to confirm a CLDN16 multi-exon deletion. Direct sequencing revealed a normal
CLDN19 sequence and suggested a large deletion in the CLDN16 gene. Multiplex ligation-dependent probe amplification
showed a homozygous CLDN16 multi-exon deletion (E2_E5del). The patient initiated conventional treatment for familial
hypomagnesemia with hypercalciuria and nephrocalcinosis and progressed to end-stage kidney disease after five years.
Conclusions: This study provides the first report of a large homozygous deletion in the CLDN16 gene causing familial
hypomagnesemia with hypercalciuria and nephrocalcinosis with late onset of the first symptoms. This description
expands the phenotypic and genotypic characterization of the disease. The late-onset chronic kidney disease in the
presence of a homozygous deletion in the CLDN16 gene reinforces the great variability of genotype-phenotype
manifestation in patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
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Familial hypomagnesemia with hypercalciuria and nephro-
calcinosis (FHHNC) is a rare autosomal recessively inher-
ited tubulopathy that is characterized by excessive calcium
and magnesium renal excretion. FHHNC patients har-
bor homozygous or compound heterozygous mutations
in the CLDN16 (OMIM248250) or CLDN19 genes* Correspondence: nevesfar@gmail.com
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creativecommons.org/publicdomain/zero/1.0/(OMIM248190), which encode the tight junction structural
proteins claudin-16 [1] and claudin-19 [2], respectively.
Claudin-16 and −19 belong to a large protein family
comprising at least 27 different isoforms in mammals.
Claudin-16 expression is restricted to the medullar and
cortical thick ascending limb of the loop of Henle (TAL)
and the distal convoluted tubule [3]. Claudin-19 co-
localizes with claudin-16 in the kidney and is expressed
in the retinal epithelium [2] and in myelinated peripheral
neurons [4]. At the TAL, both claudin-16 and claudin-19
cis-interact to form a selective paracellular cation channels article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Biochemical serum and urine analysis of the proband
at the age of diagnosis (20 years old) through to the age when
she began peritoneal dialysis (25 years old)
Exam (reference values) Age (years)
20 21 22 23 24 25
Serum calcium (8.3–10.6 mg/dL) 7.1 8.3 9.1 7.9 7.5 10.9
Serum magnesium (1.3–2.7 mg/dL) 0.9 1.3 1.2 1 0.9 0.9
Uric Acid (2.6–6.0 mg/dL) 7.5 7.5 11.9 11.8 12.2 13.1
Creatinine (0.50–1.10 mg/dL) 1.9 2.1 2.4 3.7 4.8 5.6
iPTH (12–72 pg/mL) 120 321 305 542 900 2620
Urea (19–49 mg/dL) 72 84 85 84 137 220
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strated varying roles of each protein in the complex [5, 7,
8], it is currently well accepted that the claudins interact
to play a pivotal role in the generation of transepithelial
NaCl diffusion potential in the tubular lumen, which
drives the paracellular force for magnesium and calcium
reabsorption [9, 10].
The onset of the first symptoms of FHHNC often occurs
during infancy and is characterized by recurrent urinary
tract infections, nephrolithiasis, polyuria, polydipsia, and,
in some cases, tetanic convulsions. Biochemical findings
include elevated serum intact parathyroid hormone levels,
incomplete distal renal tubular acidosis, hypocitraturia,
hyperuricemia, and an impaired glomerular filtration rate
[1, 2, 11, 12]. In addition, patients with CLDN19 muta-
tions usually present severe ocular abnormalities such as
macular coloboma, nystagmus, retinopathy, and visual loss
[2, 12–14]. In patients with CLDN16 mutations, milder
visual disturbances such as myopia, astigmatism, hyper-
metropia, and/or strabismus have been described [1, 11].
To date, about 50 different mutations have been re-
ported in the CLDN16 gene (40 missense/nonsense, 5 spli-
cing, 3 small deletions, and 2 small indels), and 15
mutations have been reported in the CLDN19 gene (13
missense/nonsense, 1 small deletion, and 1 large deletion)
(http://www.hgmd.cf.ac.uk). Functional studies have dem-
onstrated that CLDN16 mutations may induce partial or
complete loss of protein function [12, 15]. Usually, muta-
tions that result in complete loss of function of both alleles
induce a phenotype with earlier onset of the symptoms
and a more rapid decline of the glomerular filtration rate
[12, 15]. By contrast, mutations resulting in partial loss of
function seem to display a slower progression to end-stage
renal disease. However, in some cases, no genotype-
phenotype correlation was observed [1, 16, 17].
In the present study, we describe, for the first time, an
FHHNC patient who presented a multi-exon deletion in
the CLDN16 gene and late onset of symptoms. This de-
scription opens new avenues for understanding the import-
ance of claudin-16 in calcium and magnesium homeostasis
in humans, as well as its role in disease.FECa (<0.20) 3.78 4.24 3.53 3.03 2.5 2.7
FEMg (3–5) 14.6 15.8 19.1 28.9 20.4 19.3
Urinary pH (4.8–7.0) 7 7 6.5 6 5 6.5
Glomerular Filtration Rate
(81–134 mL/min 1.73 m2)
51 45 34 33 25 11
At the age of diagnosis, the patient presented high levels of uric acid, urea,
and intact parathyroid hormone. At age 20, she presented stage 3, moderate
chronic kidney disease (CKD). She presented high fractional excretion of
calcium and magnesium. In six years, she progressed to end-stage kidney
disease. Formulas: FECa (Ca(U) X Cr(S)/Ca(S) X Cr(U) X 100); FEMg (Mg(U) X
Cr(S)/Mg(S) X Cr(U) X 100); Glomerular Filtration Rate: [140 – age (years) X
weight (kg)/72 X Cr(S) (mg/dL) X 0.85 (female)]. Abbreviations: iPTH, intact
parathyroid hormone; FECa, fractional excretion of calcium relative to
creatinine; FEMg, fractional excretion of magnesium relative to creatinine; Ca,
calcium; Mg, magnesium; U, urinary; S, serum; Cr, creatinineCase presentation
Clinical characteristics
The proband was born from consanguineous parents
(first-degree cousins). She was the only daughter of a
Brazilian Caucasian couple. The father was reported to
be healthy but he could not be examined because he was
living in another city. The mother was also healthy and
did not have a medical history of nephrolithiasis or urin-
ary infection. Her plasmatic and urinary biochemical
analysis presented normal values, and the ultrasound did
not reveal any evidence of renal disease.The proband presented normal development and growth
and reported to be healthy until the age of 20 years, when
she started to complain of frequent abdominal and joint
pain. Serum and urinary biochemical exams revealed hy-
percalciuria, hypomagnesemia, and increased levels of tri-
glycerides, uric acid, urea, and intact parathyroid hormone,
with moderate chronic kidney disease (CKD), diagnosed at
stage 3 (Table 1). Her serum calcium level was also under
the lower limit. The fractional excretions of calcium and
magnesium were high, suggesting FHHNC (Table 1). Al-
though there was no medical history of nephrolithiasis or
recurrent urinary tract infections, nephrocalcinosis was de-
tected under renal ultrasound. Moreover, bone densitom-
etry demonstrated osteoporosis in the femur. Ophthalmic
exams revealed only mild myopia.
When diagnosed, the patient began treatment with mag-
nesium citrate (1 g/day), hydroclorotiazide (25 mg/day),
calcitriol (0.25 μg/day), calcium carbonate (1 g/day), alo-
purinol (300 mg/day), and followed the recommendation
of high ingestion of water (at least 3 L/day). In the follow-
ing years, the dosages were slightly changed according to
the disease progression. The patient followed all the rec-
ommendations and adhered to the proposed treatment,
but after five years her renal function rapidly progressed
to end-stage kidney disease (glomerular filtration rate de-
creased from 51 to 11 mL/min 1.73 m2) and she initiated
peritoneal dialysis at the age of 26.
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sent form, in accordance with the ethical standards of the
responsible national committee on human experimenta-
tion (CONEP 1440/2001) and the Helsinki Declaration.
They were subjected to physical examination, including
ophthalmic exams, and serum and urine biochemistry ana-
lysis. The diagnosis of nephrocalcinosis was made based on
results of renal ultrasonography. Ophthalmic exams were
conducted to determine the presence of myopia, pigmen-
tary retinitis, macular coloboma, strabismus, astigmatism,
and/or nystagmus.
Molecular analysis and multiplex ligation-dependent
probe amplification (MLPA)
For molecular analysis, venous blood was collected and
genomic DNA was isolated from leukocytes using Wizard
Genomic DNA Purification Kit (Promega; Madison, WI,
USA). DNA fragments of the human CLDN16 and
CLDN19 gene-coding regions and exon-intron boundaries
were amplified using gene-specific primer sets (CLDN16
primers sets had been previously described by Simon et al.
[3] and CLDN19 primers sequences were kindly provided
by Dr. Martin Konrad/ University Children’s Hospital,
Munster, Germany). Polymerase chain reaction (PCR)
products were purified and subject to bidirectional DNA
sequencing reactions using the BigDye3.1 terminator in an
ABI3730 sequencer (ABI Prism) at a genomic core facility
(Macrogen Inc.; Seoul, Korea). Sequencing results were
compared to the CLDN16 and CLDN19 reference se-
quences available at ENSEMBL (www.ensembl.org).
After conventional PCR and sequencing of the
CLDN16 and CLDN19 genes, synthetic MLPA probes
were designed to confirm the suspicion of a CLDN16
partial deletion. The target sequence of each synthetic
half probe was designed according to the specifications
described by Stern et al. [18]. Probe pairs for exons 3
and 5 of the CLDN16 gene were designed. Two control
probe pairs for the VIPR2 and KIAA0056 genes were in-
cluded in the probe set. MLPA reactions were performed
following the standard protocol (MRC-Holland protocol;
http://www.mlpa.com). Trace data were analyzed using
the Gene Mapper v4.0 software (Applied Biosystems;
Foster City, CA, USA), and the integrated peak areas
and heights were exported to an Excel spreadsheet
(Microsoft; Silicon Valley, CA, USA). For each sample,
the peak heights were first normalized to the average peak
height of the control probes, followed by normalization to
the average peak height of control samples, obtained from
healthy and non-related patients, included in the run. The
sample run was considered acceptable if the ratio to the
control probe pairs was between 0.8 and 1.2. The thresh-
old value for deletion was set to 0.75.
Direct sequencing of the CLDN19 coding regions of
the proband did not reveal any mutations or singlenucleotide polymorphisms. In the CLDN16 gene, exon 1
and the promoter region were amplified and presented
the normal sequences. However, after several attempts,
it was not possible to amplify this gene from exon 2
through exon 5, suggesting a homozygous gene deletion.
Under MLPA analysis, the probes designed for exons 3
and 5 presented half the expected signal in the mother.
In the proband, there was no amplification, thus suggest-
ing a homozygous gene deletion (Fig. 1). The control
genes could be normally amplified (Fig. 1).
Claudin and FHHNC
Claudin proteins contain four domains: a short intracel-
lular N-terminus, four transmembrane domains, two
extracellular loops, and a long C-terminal cytosolic tail.
The first extracellular loop appears to line the paracellu-
lar pore and determines the protein’s selectivity, whereas
the second extracellular loop mediates trans interactions
[19]. The C-terminal cytosolic tail plays roles in protein
trafficking to the tight junction and in protein stability
[19]. To date, about 50 different CLDN16 mutations
have been identified in FHHNC patients in the coding
regions of all four domains (http://www.hgmd.cf.ac.uk).
The present case represents the first report of a patient
with a large deletion from exon 2 to 5 of CLDN16,
which likely induced complete loss of protein function.
Functional assays have revealed that different mutant
proteins can display normal trafficking to the cell mem-
brane or remain in the cell, localized either to lysosomes
or to the endoplasmic reticulum. Moreover, even when
they are properly targeted to the tight junctions, some
claudin-16 mutants (p.L145P, p.L151F, p.G191R, p.A209T,
and p.F232C) fail to interact with claudin-19, thereby
impairing the synergistic effect of the complex. This re-
sults in partial or complete disruption of calcium and
magnesium homeostasis [5, 15, 20]. The heterodimeric
claudin-16 and claudin-19 interaction is reported to be es-
sential for the divalent cations selectivity of the paracellu-
lar channels at the TAL [5, 6]. Other studies using RNA
interference showed that all mutations that disrupted this
interaction abrogated the function of the whole complex
[21]. Experimental animal models demonstrated that the
silencing of either the Cldn16 or Cldn19 gene resulted in
the absence of the other protein (claudin-19 or claudin-16,
respectively) at the tight junctions in the TAL [6].
To date, it is not possible to predict which of the two
proteins is more important for calcium and magnesium
homeostasis. In 2012, Godron et al. compared the renal
progression of patients with CLDN16 and CLDN19 mu-
tations, and observed that patients with CLDN19 muta-
tions showed a more severe decline. However, they
assumed that the mutation types in this cohort of
patients were more severe in the CLDN19 group, includ-
ing a large deletion and frameshift mutations [12].
Fig. 1 Pherograms corresponding to the electrophoresis of the
multiplex ligation-dependent probe amplification assay (a: mother;
b: proband; c: control sample). The first two peaks (arrows) represent
annealing of the CLDN16 probes to the genomic DNA. The last two
peaks are the two control probes. Notice the two first peaks in the
control sample (c), the absence of these peaks in the proband (b),
and half of the peak height in the mother (a). The control probes
remained constant in all samples
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diagnosis is during infancy. In 2008, Konrad et al. evalu-
ated 23 patients with different CLDN16 mutations that in-
duced a complete loss of function [15]. They observed
that the median age for the onset of the first symptoms
was 2.2 years; approximately 30 % of these patients pre-
sented CKD at diagnosis, and 50 % required renal replace-
ment therapy by age 15 [15]. Other studies comprising
FHHNC patients with complete loss of function of
claudin-16 reported the median age of the first symptoms
ranging from 0.1 to 7 years, and the age of clinical diagno-
sis ranging from 0.5 to 12 years [1, 12, 22, 23]. Our patient
presented the first symptoms only at 20 years of age, and
the biochemical exams revealed moderate CKD. Her renal
function was surely altered before diagnosis, but she hadno previous history of urinary infection or any symptom
of renal disease.
This is the first report of FHHNC caused by a large
deletion in the CLDN16 gene. To date, there is only one
case report of a large deletion in the CLDN19 gene,
which was detected in a Tunisian family. However, the
individual phenotypes of the patients were not described
[12]; therefore, we could not compare our results with
these patients with respect to the disease progress and
renal phenotype. Although we have not performed func-
tional assays, we hypothesize that this multi-exon dele-
tion observed in our patient induced a complete loss of
function of claudin-16, which consequently affected the
function of the whole heterodimer.
In 2010, a study using Cldn16 knockout mice yielded in-
teresting results concerning the age of onset of hypomag-
nesemia. Neonatal animals exhibited normomagnesemia,
while juvenile animals presented only mild hypomagnes-
emia [9]. The late onset of hypomagnesemia was triggered
by a further decrease in claudin-19 levels during develop-
ment. Claudin-19 expression decreased with age (30 %
lower expression in adult mice) accompanied by upregula-
tion of several other calcium and magnesium transport
systems, including Trpv5, Trpm6, calbindin-D9k, Cnnm2,
and Atp13a4. In addition, these animals did not develop
nephrocalcinosis and kidney failure, suggesting that there
may be compensatory mechanisms in this model that
cause calcium and magnesium homeostasis in the absence
of claudin-16 [9].
The expression of other claudin isoforms in the kidney
has been described, but their role in the control of the
selectivity and permeability of divalent cations in the
kidney remains unclear [24, 25]. Apparently, the deple-
tion of either claudin-16 or claudin-19 does not affect
the expression and localization of other claudins such as
claudin-10 and claudin-18, and of other normal constit-
uents of TAL tight junctions, such as occludin and
zonulla occludens-1 [26]. Therefore, it is likely that other
proteins are involved in the modulation of disease pro-
gression or contribute to the differences in the pheno-
type and biochemical features among FHHNC patients.
The hypothesis of the influence of modulators and epi-
genetic factors in the clinical spectrum of FHHNC is re-
inforced by studies that report unusual clinical findings
in FHHNC patients with CLDN16 mutations [27–29]
and different clinical courses in siblings with the same
CLDN16 mutation [17, 30]. One case report presented a
boy with a truncating mutation in claudin-16 (p.W237X)
with early-onset renal insufficiency, horseshoe kidney,
neonatal teeth, atypical face, cardiac abnormalities, umbil-
ical hernia, and hypertrichosis [27]. Another study re-
ported a female patient who experienced recurrent
passages of kidney stones and urinary tract infections as of
4 years old, and only developed nephrocalcinosis when
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ities (hypospadias and cryptorchidism) were observed in
one of the proband’s siblings [29]. A rare case report de-
scribed a patient who, in addition to the classical symp-
toms of FHHNC, was diagnosed with smaller kidneys,
severe bone disease, severe metabolic acidosis, and persist-
ent hypocalcemia. Intriguingly, several siblings within the
family had died previously without a clear diagnosis [30].
Therefore, there is current evidence that FHHNC may
present great variability among patients, with respect
to both the clinical manifestation and the genotype-
phenotype correlation. The reason that our patient
only showed the first symptoms at the age of 20 years
old remains unknown, and the role of compensatory
mechanisms, epigenetic effects, or other factors merits
further investigation.
Conclusions
Although mutations in CLDN16 that induce a complete
loss of function seem to usually appear early in infancy
and progress to CKD at puberty, the phenotype-genotype
correlation is not yet completely established. In our pa-
tient, the late onset of CKD followed by rapid decline of
renal function suggest that further studies are necessary to
better explain the differences observed in the clinical
course of this disease among patients. This study reports,
for the first time, a case of FHHNC due to a multi-exon
deletion (E2_E5del) in the CLDN16 gene, and contributes
to improving the phenotype-genotype characterization in
these patients.
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